Citi analyst Geoff Meacham raised the firm’s price target on Gilead (GILD) to $135 from $125 and keeps a Buy rating on the shares. Citi’s survey of 100 physicians indicates strong initial trends for the Yeztugo launch in HIV, the analyst tells investors in a research note. The firm upped sales forecasts and the price target as a result.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strategic Positioning and Extended Patent Protection Justify Buy Rating
- Wells says Biktarvy patent settlement ‘big deal’ for Gilead at, $6-$12 upside
- Gilead Sciences Settles Patent Litigation on Biktarvy
- Gilead settles patent litigations with Biktarvy ANDA filerers
- Gilead Sciences: Strategic Diversification and Promising Inflammation Pipeline Justify Buy Rating